study question: Do high-risk patients who develop severe early ovarian hyperstimulation syndrome (OHSS) and receive low-dose GnRH antagonist in the luteal phase have lower live birth rates compared with high-risk patients who do not develop severe early OHSS and do not receive GnRH antagonist in the luteal phase?
Introduction
The use of GnRH antagonists in the follicular phase for the prevention of premature LH surges has been extensively reviewed in the literature, with numerous clinical trials, Cochrane reviews and metaanalyses available regarding the analogue's safety, efficacy and optimization (Al-Inany and Aboulghar, 2002; Kolibianakis et al., 2006; Al-Inany et al., 2007 .
However, limited data exist regarding the use of GnRH antagonists in the luteal phase. Luteal GnRH antagonist administration has been studied in vivo in a small number of animal studies focusing on hormonal changes and pregnancy outcome (Das and Talwar, 1983; Siler-Khodr et al., 1984; Eley, 1987; Fraser et al., 1987; Kang et al., 1989; Virolainen et al., 2003; Tug et al., 2011) .
In humans, GnRH antagonist administration during the mid-luteal phase of a natural menstrual cycle is known to induce luteolysis by reducing pulsatile gonadotrophin stimulation, resulting in the rapid decline in serum estradiol and progesterone levels and the onset of menstrual bleeding (Mais et al., 1986) .
Moreover, in vitro studies have shown that GnRH antagonists influence placental hormone release (Siler-Khodr et al., 1983 , 1987 , but not decidualization of endometrial cells (Klemmt et al., 2009) .
In patients treated by IVF, the majority of relevant studies involve luteal GnRH antagonist administration in the preceding luteal phase prior to the onset of ovarian stimulation for the purpose of follicular synchronization or prevention of premature LH surges (Fanchin et al., 2004; Friden and Nilsson, 2005; Humaidan et al., 2005a; DiLuigi et al., 2011; Garcia-Velasco et al., 2012) .
However, luteal phase GnRH antagonist administration has also been proposed for a different purpose, that of managing established severe early ovarian hyperstimulation syndrome (OHSS) (Lainas et al., 2007b (Lainas et al., , 2009a (Lainas et al., ,b, 2012 Bonilla-Musoles et al., 2009,) . It has been reported that luteal GnRH antagonist administration in patients with established severe early OHSS appears to prevent patient hospitalization and results in quick regression of the syndrome on an outpatient basis (Lainas et al., 2007b (Lainas et al., , 2009b . This intervention appears to be effective in both agonist and antagonist-treated patients. In addition, there is some evidence to suggest that luteal GnRH antagonist is safe and efficient when administered concomitantly with embryo transfer in patients with severe early OHSS, leading to the birth of healthy offspring (Lainas et al., 2009a) . However, the available published data exist in the form of a small case series (Lainas et al., 2009a) , which, although promising, requires further evaluation.
The aim of the present study was to investigate IVF and neonatal outcomes in patients with severe early OHSS, who received luteal GnRH antagonist administration, compared with a control group of high-risk patients, who did not develop severe OHSS and did not receive GnRH antagonist in the luteal phase.
Materials and Methods

Patient population and management
This prospective study included patients at high risk for OHSS, who underwent ovarian stimulation for IVF between January 2009 and December 2011 at Eugonia Assisted Reproduction Unit.
Patients were younger than 40 years of age, with polycystic ovaries (The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group, 2004) , at high risk for OHSS [defined by the presence of at least 20 follicles ≥11 mm on the day of triggering of final oocyte maturation (Papanikolaou et al., 2010) ] and not willing to cancel embryo transfer and cryopreserve all embryos, even if severe early OHSS was diagnosed by Day 5 of embryo culture.
Blastocyst transfer allowed more extensive monitoring of high-risk patients in order to accurately diagnose the development of severe early OHSS, as previously proposed (Papanikolaou et al., 2011; Lainas et al., 2012) .
Patients were allocated in two groups depending on the development or not of severe early OHSS. The control group included patients who did not develop severe OHSS. Patients diagnosed with severe early OHSS on Day 5 post-oocyte retrieval were presented with two options: (i) GnRH antagonist administration combined with embryo transfer cancellation and cryopreservation of all embryos (OHSS + cryopreservation group), which is the standard procedure followed for severe OHSS in our Unit (Lainas et al., 2009b) ; (ii) transfer of one or two blastocysts with concomitant initiation of GnRH antagonist administration and luteal phase support, in order to reduce the severity of the established OHSS, as well as to reduce the chance of pregnancy-induced late OHSS (OHSS + antag group).
The option for fresh embryo transfer was proposed after careful consideration of all the risks involved and after thorough discussion with the patients, explaining in detail all the reasons for caution regarding the method. We expressed our reservations about the development of late pregnancy-induced OHSS, the lack of solid bibliographic evidence due to the novelty of the method apart from a small case series (Lainas et al., 2009a) and the potential adverse effects of GnRH antagonist administration on pregnancy outcome.
The intervention was approved by the Centre's Institutional Review Board. Patients signed an informed consent form regarding risks of early and late OHSS, and risks of the intervention proposed. Institutional Review Board authorization and patient consents were also obtained for the additional monitoring of patients with severe early OHSS after embryo transfer.
Criteria for the diagnosis of severe OHSS Severe OHSS was diagnosed using previously published criteria . Briefly, severe early OHSS was diagnosed in the presence of moderate/marked ascites and at least two of the following criteria: enlarged ovaries (.100 mm maximal diameter), haematocrit (Ht) .45%, white blood cell count (WBC) .15 000/mm 3 , hydrothorax, dyspnoea, oliguria or abnormal liver function tests, based on a modification of previous classification systems (Schenker and Weinstein, 1978; Golan et al., 1989; Navot et al., 1992; Rizk and Aboulghar, 1999; Pau et al., 2006; Alvarez et al., 2007b; Lainas et al., 2010; Humaidan et al., 2010b) .
Ascites was classified according to the quantity of fluid accumulation in the peritoneal cavity (Table I) , as already described , similar to previously published criteria (Pau et al., 2006; Humaidan et al., 2010b) .
Description of the intervention
In patients with early severe OHSS, 0.25 mg of the GnRH antagonist ganirelix (Orgalutran, Organon, The Netherlands) was administered daily for 3 days, starting on the day of embryo transfer (Day 5) until and including Day 7 post-oocyte retrieval (Lainas et al., 2007b, a,b) .
In all patients included, luteal phase support was performed by administering micronized progesterone (600 mg) (Utrogestan, Laboratoires Besins International SA, France) from Day 3 post-oocyte retrieval until the 10th week of gestation, if pregnancy occurred. Additionally, patients with severe OHSS receiving the intervention were administered 17b-estradiol patches (Dermestil TTS-100, Lohmann Therapie-Systems GmbH, Germany) from Day 5 until the 7th week of gestation and 4500 anti-Xa IU (0.45 ml) tinzaparin sodium (Innohep; LEO Pharmacutica Products Hellas Ltd, Greece) for thromboprophylaxis, daily from Day 5 post-oocyte retrieval until resolution of the syndrome.
Ovarian stimulation
Patients underwent ovarian stimulation for IVF/ICSI using either a long GnRH agonist down-regulation or a flexible GnRH antagonist protocol, as previously described (Lainas et al., 2010) .
All patients received oral contraceptive pills (Trigynera, Bayer Hellas, Greece) daily for 21 days, starting on Day 2 of spontaneous menses of the preceding cycle, after a blood test confirmed the presence of a baseline hormone profile.
The starting dose of rFSH was 150 IU/day for all patients. This dose was adjusted after Day 5 of stimulation, depending on the ovarian response, as assessed by E2 levels and ultrasound.
Triggering of final oocyte maturation and IVF
When at least three follicles of diameter ≥17 mm were present, final oocyte maturation was triggered by i.m. injection of 5000 IU hCG (Pregnyl; Organon, The Netherlands), as previously described (Abdalla et al., 1987; Kolibianakis et al., 2007) . Transvaginal ultrasound-guided oocyte retrieval was performed 36 h later by double lumen needle aspiration. ICSI was performed only in cases with severe male factor or previous fertilization failure. Embryos were cultured in sequential media (Medicult/Origio, Denmark) for 5 days to the blastocyst stage.
All patients were examined again 15 and 30 days (in case of positive hCG test) after oocyte retrieval for the presence of late pregnancyinduced OHSS.
Follow-up of patients after the intervention
In patients with severe early OHSS who received the intervention, ultrasound assessment of ovarian size and ascetic fluid and measurement of serum estradiol, progesterone, Ht and WBC were performed on Days 5, 7, 9 and 11 post-oocyte retrieval. In addition, serum estradiol, progesterone, Ht and WBC were also evaluated on the day of oocyte retrieval (Day 0). Ovarian volume was calculated using the prolate ellipsoid formula V ¼ D1 × D2 × D3 × 0.523, where D1, D2 and D3 are the three maximal longitudinal, antero-posterior and transverse diameters, respectively.
Follow-up of children born
Congenital malformations, birthweight and gestational age of delivery were recorded for children born in the control and OHSS + antag groups.
Major congenital malformations were defined as congenital malformations that cause functional impairment or require surgical intervention, according to the definition proposed by Bonduelle et al. (2002 Bonduelle et al. ( , 2010 . All remaining congenital malformations were defined as minor.
The data were collected from respective parents by a certified midwife. The patient's paediatrician was contacted in case of congenital malformations for further information regarding the type and severity of the malformation.
Ultrasound and laboratory assays
All ultrasound measurements were performed using a 7.5 or 6 or 5 MHz vaginal probe (Sonoline Adara, Siemens). FSH, LH, E 2 and progesterone levels were measured using an Immulite analyser and commercially available kits (DPC, Los Angeles, CA, USA). Analytical sensitivity were 0.1 mIU/ml for FSH, 0.1 mIU/ml for LH, 15 pg/ml for E 2 and 0.2 ng/ml for progesterone. Intra-and inter-assay precisions at the concentrations of most relevance to the current study (expressed as coefficients of variation) were 2.6 and 5.8% for FSH, 5.9 and 8.1% for LH, 6.3 and 6.4% for E2 and 7.9 and 10% for progesterone. Ht and WBC count were determined by flow cytometry using Coulter A The classification of ascites used in our Unit is similar to previously published criteria (Pau et al., 2006; Humaidan et al., 2010b) and distinguishes different levels of ascites, depending on the accumulation of ascetic fluid when the patient was at the anti-trendelenburg position.
Live births after luteal GnRH antagonist for OHSS imprecision limits for white (WBC) and red blood cell count (RBC), was 3%. Ht was computed from the relative volume of erythrocytes [mean corpuscular
Outcome measures
The primary outcome was live birth rate per embryo transfer. Secondary outcomes included positive hCG rates, clinical and ongoing pregnancy rates (presence of gestational sac with fetal heart beat detection at 6 -7 weeks and at 12 weeks of gestation, respectively), multiple pregnancy rates, as well as biochemical pregnancy rates (positive hCG not reaching clinical pregnancy) and clinical spontaneous abortion rates (clinical pregnancy not reaching ongoing pregnancy at 12 weeks). Major and minor congenital malformations, psychomotor problems, as well as birthweight and gestational age of delivery of children born were recorded in the two groups. In addition, progression or regression of severe OHSS was studied in terms of alterations in serum estradiol, progesterone, Ht, WBC count, ovarian volume and ascites following luteal GnRH antagonist administration in patients with established severe OHSS. The mean daily dose of GnRH antagonist per kg was also calculated in patients with severe OHSS receiving the intervention.
Statistical analysis
The outcome measures were subjected to Fisher's exact test or repeated measures ANOVA followed by post hoc pairwise comparisons with Bonferroni correction. The frequency distributions of the ascites levels were analysed using the Wilcoxon test. The level of significance was set at 0.05.
Results
A total of 194 patients at high risk for OHSS who underwent embryo transfer on Day 5 were included in the study. Of these, 22 patients were diagnosed with severe early OHSS on Day 5, while 172 patients did not develop severe early OHSS (control group). All 22 patients with severe early OHSS wished to proceed to embryo transfer and luteal administration of GnRH antagonist (OHSS + antag group). No patient selected embryo transfer cancellation and cryopreservation of all embryos, because they had either experienced previous cancelled IVF cycles due to OHSS (n ¼ 8) or did not wish to cancel the current cycle and compromise embryo viability following cryopreservation (n ¼ 13). Thus, all 22 patients opted to proceed to embryo transfer using the new treatment approach proposed here (Fig. 1) .
Baseline characteristics, ovarian stimulation and embryological data in the two groups compared are shown in Table II . Patients in both groups were at high risk for OHSS on the day of triggering final oocyte maturation (presence of at least 20 follicles .11 mm at ultrasound scan) and had similar numbers of oocytes retrieved and embryos transferred, allowing valid comparisons between them.
Live birth rates (40.9 versus 43.6%) were similar in the OHSS + antag and control groups, respectively. In addition, positive hCG rates (72.7 versus 75.0%), clinical pregnancy rates (50.0 versus 65.1%), ongoing pregnancy rates (45.5 versus 48.8%) and multiple pregnancy rates (37.5 versus 44.2%) did not differ between the OHSS + antag and the control group (Table III) . Biochemical pregnancy rates (31.3 versus 13.2%) and clinical spontaneous abortion rates (9.1 versus 24.1%) did not differ statistically, although the higher incidence of biochemical pregnancy in OHSS + antag patients compared with control patients was close to statistical significance (P ¼ 0.07) (Tables III and IV) .
There were 9 deliveries with 14 live infants born (4 singleton and 5 twin deliveries) in the OHSS + antag group and 75 deliveries with 103 live infants born in the control group (47 singleton and 28 twin deliveries). No stillbirths or intrauterine deaths were recorded in either group.
The duration of gestation (36.9 + 0.9 weeks versus 36.9 + 2.4 weeks; P ¼ 0.9) and neonatal weight (2392 + 427 versus 2646 + 656 g; P ¼ 0.22) were similar in the OHSS + antag and control groups, respectively (Tables V and VI) .
There were three cases of major congenital malformations in children born in the control group [3/103(2.9%)]: one child with atrial/ ventricular septal defect, one with hypospadias and one with aortic obstruction. No major congenital malformation were observed in children born in the OHSS + antag group [0/14 (0%)] (Tables V and VI) .
In addition, four children in the control group needed treatment for speech disorders, compared with no children in the OHSS + antag group. No minor congenital abnormalities or psychomotor problems were observed in either group.
The high-risk patients who developed severe early OHSS received low-dose (0.25 mg) luteal GnRH antagonist administration for 3 days. Patient weight (mean + SD) was 66.1 + 12.6 kg and the GnRH antagonist daily dose administered per kg (mean + SD) was 0.0039 + 0.0008 mg/kg. Ovarian volume, ascites, serum estradiol, progesterone, Ht and WBC count reached their highest levels on the day of severe OHSS diagnosis (Day 5 post-oocyte retrieval). There was a rapid and statistically significant improvement of ultrasound and laboratory findings, beginning as early as 2 days after luteal administration of GnRH antagonist in all 22 patients. The decline in all parameters continued in a progressive manner until the end of the monitoring period (Fig. 2) .
All 22 patients with established early severe OHSS were managed with luteal GnRH antagonist administration and frequent monitoring at an outpatient level. No patient required hospitalization, or received cortisone administration, or had paracentesis of ascetic fluid. No patient developed late OHSS in either group.
Discussion
The present study suggests, for the first time, that luteal GnRH antagonist administration concomitantly with embryo transfer in patients with established severe early OHSS does not compromise the chance of a successful pregnancy outcome. The data obtained suggest that high pregnancy and live birth rates are maintained in patients with severe early OHSS, who received low-dose GnRH antagonist, compared with those observed in the control group of high-risk patients, who did not develop severe OHSS and did not receive GnRH antagonist.
The incidence of biochemical pregnancy in the OHSS + antag group appeared higher, although not significantly so (P ¼ 0.07). It has to be noted that, significantly higher biochemical pregnancy rates were previously shown in women with early OHSS compared with non-OHSS patients (Papanikolaou et al., 2005) . In addition, there is evidence showing that severe OHSS is associated with increased spontaneous abortion rates and pregnancy complications (Abramov et al., 1998; Raziel et al., 2002 Raziel et al., , 2009 ). Therefore, it seems likely that this increase, albeit non-significant, in biochemical pregnancy rates in our study may be attributed to the presence of severe early OHSS. However, a possible deleterious effect of luteal administration of GnRH antagonist on extra-pituitary reproductive cells and organs, such as ovarian cells, oocyte, embryo and endometrium cannot be entirely excluded (Kol, 2000) .
The administration of GnRH antagonist during the peri-implantation period may raise some concerns regarding potential adverse effects of the antagonist on embryo implantation, pregnancy establishment and progression, as well as the health of the children born following the intervention. The current study suggests that pregnancy and live birth rates are similar between the two patient groups compared and do not seem to be affected by luteal administration of GnRH antagonist. All children born in the OHSS + antag group were healthy without any major or minor congenital abnormalities. In addition, the duration of gestation and neonatal weight were similar to those recorded in the control group. These observations are promising regarding the effect of luteal GnRH antagonist administration, although Figure 1 Flow chart of the study design.
Live births after luteal GnRH antagonist for OHSS the number of children born following the intervention is very small and therefore larger studies are necessary to verify the present findings.
The incidence of major congenital malformations in the control group of patients was 2.9%. Previous studies have reported an incidence ranging from 3.4 to 4.5% (Ludwig et al., 2001; Boerrigter et al., 2002) , while the largest follow-up study to date comparing congenital malformations in 2000 fetuses born after ovarian stimulation using GnRH antagonist and GnRH agonist protocols reported an incidence of 5 and 5.4% in antagonist and agonist protocols, respectively (Bonduelle et al., 2010) .
Only a limited number of studies in animal species are available regarding post-implantation GnRH antagonist administration, and these show that the antagonist has a dose-dependent and gestational age-dependent effect on pregnancy progression and fetal outcome. In the baboon model, high doses of GnRH antagonists ranging from 3.6 to 100 mg were administered over 7 days during more advanced stages of early pregnancy (35-45 days of gestation). There was a dose-dependent increase in stillbirths following those high doses of Kang et al., 1989) . Similarly, a single dose of 0.1 mg/kg resulted in a 20% abortion rate in pregnant pigs (Virolainen et al., 2003) . However, a lower dose of 2 mg GnRH antagonist administered on Days 14-19 in pregnant baboons did not seem to have an adverse effect on pregnancy outcome (Eley, 1987) . In rats, GnRH antagonist doses ranging from 0.015 to 0.15 mg/kg on Days 4 or 8 of gestation were associated with lower birthweight and altered histomorphometric characteristics in a dose-dependent manner (Tug et al., 2011) . It is clear that the doses administered in all the above animal studies are very high compared with the mean dose of 0.0039 mg/kg used in our study. In humans, the effect of GnRH antagonist administration on pregnancy has been studied only in vitro. It was shown that GnRH antagonist did not influence the extent of decidualization of endometrial stromal cells, and no adverse effect was exerted on human blastocyst invasion (Klemmt et al., 2009) . However, GnRH antagonists were shown to inhibit hormone release in mid-gestation human placental cell cultures by suppressing hCG, alpha-hCG, estrone, estradiol and progesterone secretion (Siler-Khodr et al., 1983 , 1987 . This inhibition was found to be gestational age related, as there was significant hormone suppression in placental cultures from 13 to 15 weeks of gestations, but no effect was seen in cells from the earlier gestational ages of 6-15 weeks (Siler-Khodr et al., 1987) .
In addition, GnRH receptors are expressed in human trophoblasts (Lee et al., 2010) , indicating that GnRH antagonists may have a direct action on the embryo. However, it is reported that GnRH stimulates only hCG production by trophoblast cells without affecting the in vitro secretion of other cytokines by trophoblasts or decidua (Lee et al., 2010) . These findings are encouraging, providing additional evidence that exposure of the embryo to GnRH antagonists is unlikely to have an adverse effect on implantation and early placental development.
In our study GnRH antagonist was administered at a low dose (0.25 mg; 0.0039 mg/kg) for only 3 days, compared with the extremely high doses for prolonged periods used in the animal studies mentioned above. The low dose of 0.25 mg of ganirelix has an elimination half-life of only 13 h (Mannaerts and Gordon, 2000) . Gastrulation in the human embryo, i.e. the formation of the three primary germ layers (ectoderm, endoderm and mesoderm) occurs in the third week post-fertilization, while the essential parts of the placenta are established and become functional by the fourth week post-fertilization (Langman, 1981) . Therefore, following the last daily 0.25 mg dose on Day 7 post-oocyte retrieval (i.e. Day 6 post-fertilization) the GnRH antagonist should have been completely eliminated well before these critical events in early embryo development occur.
Regarding OHSS evolution, this study shows that successful outpatient management of severe OHSS with antagonist treatment in the luteal phase is feasible and is associated with rapid regression of the syndrome. The efficiency of luteal GnRH antagonist is supported by an increasing number of patients with severe OHSS who have been successfully treated using the intervention in previous reports (Lainas et al., 2007b (Lainas et al., , 2009a (Lainas et al., ,b, 2012 , as well as in the present study. Therefore, it is possible to propose GnRH antagonist administration in the luteal phase as tertiary management level of OHSS, in addition to the use of GnRH antagonist protocols for primary (2006, 2008) Eliminates development of OHSS Rescues luteal phase and allows fresh transfer following GnRH agonist trigger Similar pregnancy rates compared with triggering with hCG Recommended when peak estradiol levels ≥4000 pg/ml Can be used only in antagonist protocol Limited number of studies available Dual trigger with GnRH agonist and low-dose hCG Griffin et al. (2012 ) Shapiro et al. (2008 Higher implantation and pregnancy rates compared with agonist trigger Minimizes risk of severe OHSS Can be used only in antagonist protocol Limited data on the incidence of late OHSS 1 case of late OHSS reported Dopamine agonist Alvarez et al. (2007a ,b) Busso et al. (2010 Reduces incidence of moderate OHSS in high-risk patients May be combined with fresh embryo transfer Does not reduce incidence of severe OHSS Poor tolerability of quanigolide at high-doses Insufficient evidence on neonatal outcomes due to small number of neonates Birth defects following quanigolide administration appear higher
Continued
Live births after luteal GnRH antagonist for OHSS prevention, and the replacement of hCG with GnRH agonist for triggering final oocyte maturation for secondary prevention, as previously suggested (Griesinger, 2010) and outlined in Table VII .
It should be noted that, in our Unit, we routinely propose antagonist administration and total embryo cryopreservation, when other prevention methods have failed or have not been used leading to the development of severe OHSS. This method offers flexibility and minimizes unnecessary embryo transfer cancellations in the majority of high-risk patients who do not develop severe OHSS (88.7% of patients receiving low-dose hCG for triggering final oocyte maturation) as previously described . The alternative, fresh embryo transfer combined with antagonist administration, should not be used in everyday clinical practice for the management of patients with severe early OHSS. This new intervention requires correct evaluation and grading of OHSS, and should be used with caution by experienced practitioners, after carefully deciding which patients can have fresh embryo transfer or cryopreservation, until the current data are supported by much larger trials with follow-up of the children born.
The concept of an OHSS free clinic begins with the choice of the proper protocol in high risk for OHSS patients (Fiedler and Ezcurra, 2012) at the level of primary prevention. An increasing amount of evidence suggests that the GnRH antagonist protocol should be the protocol of choice in these patients, as it has been consistently associated with significantly lower incidence of OHSS compared with the long protocol (Al-Inany and Aboulghar, 2002; Al-Inany et al., 2007 Lainas et al., 2010) .
It may appear contradictory that some patients in the present study were treated with a long agonist protocol. However, the study period started in 2009, an era when the long protocol was still used in the majority of controlled ovarian stimulation protocols. It was only in May 2011 when the latest Cochrane review by Al-Inany et al. (2011) reversed the international skepticism against GnRH antagonist protocols. Also, the personal wish of patients/clinicians was taken into account; the worldwide use of GnRH antagonist protocols is currently estimated to be 40% of analogue cycles. Moreover, our previous publication (Lainas et al., 2009b showed that luteal GnRH antagonist administration is effective for the regression of severe OHSS in patients pre-treated not only with antagonist protocol, but also with a long agonist protocol.
In the present study, luteal GnRH antagonist administration was associated with rapid regression of severe early OHSS, shown by a significant decline in all ultrasound and laboratory parameters as early as 2 days following GnRH antagonist initiation, which continued until the end of the monitoring period for all 22 OHSS patients studied. No patients required hospitalization. A similar rapid regression of severe early OHSS following low-dose luteal GnRH antagonist administration has been previously reported (Lainas et al., 2007b (Lainas et al., , 2009a (Lainas et al., ,b, 2012 .
The absence of late OHSS in both patient groups, despite the elevated multiple pregnancy rates, may be related to the close monitoring of high-risk patients performed in the present study and the accurate diagnosis of early OHSS using our proposed strict classification system.
It was recently described that GnRH agonists and antagonists were administered in the luteal phase from the day of oocyte retrieval for a period of 7 days in order to prevent OHSS in high-risk patients (Fabregues et al., 2012) . The incidence of moderate and severe OHSS in both study groups was similar to the controls and no patients were hospitalized, suggesting that luteal administration of GnRH analogues does not reduce the incidence of OHSS. However, this study is only available as an abstract and includes a small number of patients, not offering specific OHSS incidence rates, classification criteria for OHSS, numbers of follicles and oocytes retrieved or other clinical parameters. Moreover, the study describes luteal GnRH analogue administration (starting on the day of oocyte retrieval) for the prevention of OHSS, and is therefore in a different context from our study, which describes luteal GnRH antagonist administration (starting on Day 5 post-oocyte retrieval) for the management/treatment of already established severe early OHSS. It is hypothesized that GnRH antagonist administration intervenes in the pathophysiological pathway of OHSS by inducing luteolysis, as previously proposed (Lainas et al., 2009a (Lainas et al., ,b, 2012 . Luteolysis results in the decline of secreted angiogenic ovarian factors associated with the OHSS, such as vascular endothelial growth factor (VEGF), and appears to be the key mechanism for OHSS regression (Kol, 2004) .
There are a number of studies reporting luteolysis when GnRH antagonist is administered in the preceding luteal phase of IVF patients, prior to the onset of ovarian stimulation (Fanchin et al., 2004; Friden and Nilsson, 2005; Humaidan et al., 2005a; DiLuigi et al., 2011; Garcia-Velasco et al., 2012) . However, the luteolytic effect of the GnRH antagonist in those cases was achieved mainly via a decrease in FSH and LH secretion. On the contrary, in our study it seems unlikely that the antagonist exerts a luteolytic effect by decreasing LH secretion, since LH concentrations are deeply suppressed in the luteal phase following ovarian stimulation, requiring luteal support (Tavaniotou and Devroey, 2006) . It seems, instead, that the GnRH antagonist may have a direct action on the human ovary. This hypothesis is supported by the presence of GnRH receptors in the human ovary, among other extrapituitary tissues (Engel et al., 2005; Choi et al., 2006; Cheung and Wong, 2008; Yu et al., 2011) . Indeed, GnRH antagonists have been shown to inhibit the expression of VEGF, the primary factor responsible for OHSS development, in human granulosa -luteal cell cultures (Asimakopoulos et al., 2006) .
In conclusion, low-dose luteal GnRH antagonist administration in women with severe early OHSS was associated with a favourable IVF outcome, comparable to control high-risk patients without severe OHSS and not receiving the intervention. This protocol may be used with caution for the outpatient management of severe early OHSS without compromising pregnancy and live birth rates. In addition, the fact that all infants born following the intervention were healthy with no congenital abnormalities, similar neonatal weight and similar duration of gestation compared with controls, suggests that low-dose luteal GnRH antagonist administration during the periimplantation period may be safe, although much larger studies with follow-up of the children born are required.
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